Clinical trials: Diabetes Mellitus Type 2 (T2DM)
Type 2 Diabetes Mellitus
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients
Primary Objectives: To assess in overweight to obese T2DM patients: The glucagon receptor occupancy of SAR425899 at two dose levels in the human liver with positron-emission tomography (PET) imaging using…
- Trial name
- NCT03350191
- Testing
- SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disease, often compounded by obesity, that leads to serious long-term health complications.
- Trial name
- NCT07728318
- Testing
- Tirzepatide + Standard Therapy (Intervention Group), Standard Oral Antidiabetic Drugs (OADs)
- Volunteers
- 52 people
- Sponsor
- Akhtar Saeed Medical and Dental College
Obesity
Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
This was a multi-center, randomized, placebo-controlled, participant-and-investigator-blinded, sponsor open-label study in obese participants with or without Type 2 Diabetes Mellitus.
- Trial name
- NCT05199090
- Testing
- MBL949
- Where
- 4 sites in United States
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Participants, Obesity
A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors
The main purposes of this study are: to investigate the safety and tolerability of ACI-19764 when it is administered to healthy participants and participants with cardiovascular risk factors to determine how quickly and to what…
- Conditions
- Healthy Participants, Obesity, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07463196
- Testing
- ACI-19764 at dose A1, ACI-19764 at dose A2, ACI-19764 at dose A3
- Where
- Netherlands
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Diabetes Mellitus, Type 2, Atherosclerosis
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.
- Conditions
- Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
- Trial name
- NCT00995930
- Testing
- ACZ885
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
The Effect of Remote SMBG Combined With the Application of APP on the Improvement of T2DM Management in the Community
To investigate whether strengthen community diabetes patients self-monitoring of blood glucose can improve the patient's blood glucose control under Chinese guidelines for the prevention and treatment of diabetes (CDS 2017) and…
- Trial name
- NCT03588000
- Testing
- Strengthen self-monitoring of blood glucose
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Yuwen Zhang
Type 2 Diabetes
To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.
- Trial name
- JMAD (NCT00916604)
- Testing
- AZD1656
- Where
- 2 sites in Japan
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Obesity, Morbid, Type 2 Diabetes Mellitus (T2DM)
Comparative Outcomes of One-Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass As Revisional Procedures Following Failed Restrictive Bariatric Surgery
Study Description This prospective, multicenter study aims to compare the outcomes of One-Anastomosis Gastric Bypass (OAGB) and Roux-en-Y Gastric Bypass (RYGB) as revisional procedures for patients experiencing insufficient…
- Conditions
- Obesity, Morbid, Type 2 Diabetes Mellitus (T2DM), Hypertension, Dyslipidemia
- Trial name
- COBRA stady (NCT06794892)
- Where
- Italy
- Volunteers
- 328 people
- Sponsor
- Azienda Sanitaria Locale Napoli 2 Nord
T2DM (Type 2 Diabetes Mellitus)
Nutritional Therapy for Diabetic Cardiomyopathy
The goal of this study is to determine if nutritional therapy can effectively treat/prevent T2DM and its consequent cardiomyopathy.
- Trial name
- NCT01373814
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington University School of Medicine
Type 2 Diabetes
Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.
A Phase 1b study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of ZE63-0302 administrated orally in T2DM patients.
- Trial name
- NCT07234864
- Testing
- ZE63-0302
- Where
- 10 sites in Australia, New Zealand and 1 more
- Volunteers
- 60 people
- Sponsor
- Eilean Therapeutics
Heart Failure, Diabetes Mellitus, Type 2
BIO-2-HEART: Identification of Biomarkers in T2DM and Heart Failure
The primary aim of the current study is a better understanding of the role of Type 2 Diabetes Mellitus (T2DM) in heart failure and, in particular, changes in cardiac metabolism, which may contribute to heart failure.
- Trial name
- BIO-2-HEART (NCT03323216)
- Testing
- 6-minute walk test, Study specific questionnaire, Blood collection
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- RWTH Aachen University
Type 2 Diabetes Mellitus (T2DM)
A Study of BGM0504 in Participants With Type 2 Diabetes
This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes
- Trial name
- NCT06716216
- Testing
- Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SC, Drug: Semaglutide Administered SC
- Where
- China
- Volunteers
- 537 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Diabetes
Evaluation of a Nutritional Supplement for People With Type 2 Diabetes.
The objective of this trial is to evaluate a nutritional supplement for people with Diabetes.
- Trial name
- NCT01850134
- Testing
- Experimental Study Product, Control Study Product
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Peripheral Neuropathy, Painful Diabetic Neuropathy
A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy
This is a randomized outpatient, double-blind, placebo-controlled, multiple-site study of the safety, tolerability, and exploratory efficacy of topically administered WST-057 (4% pirenzepine free base monohydrate) for 24 weeks in…
- Conditions
- Peripheral Neuropathy, Painful Diabetic Neuropathy, Diabetic Neuropathies, Painful
- Trial name
- NCT04005287
- Testing
- WST-057 (4% pirenzepine) Lose Dose 2mL, WST-057 (4% pirenzepine) High Dose 4mL
- Where
- 5 sites in Canada
- Volunteers
- 58 people
- Sponsor
- WinSanTor, Inc
Type 2 Diabetes
Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.
2 weeks screening period, 3 weeks run-in period, 16 weeks double-blind treatment period, to evaluate the Safety and Efficacy of HRS-7535 in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin and…
- Trial name
- NCT06393348
- Testing
- HRS-7535
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
T2DM (Type 2 Diabetes Mellitus)
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
This double-masked placebo-controlled study will include approximately 450 subjects with inadequately controlled T2DM on diet control alone or on diet control and metformin monotherapy.
- Trial name
- NCT04754334
- Testing
- ORMD-0801
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Oramed, Ltd.
Type 2 Diabetes Mellitus (T2DM)
Dapagliflozin Effect on Erythropoiesis and Physical Fitness
Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study
- Trial name
- NCT03423355
- Testing
- Dapagliflozin (Forxiga®), Hydrochlorothiazide 25 mg
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
Osteoporosis, Osteoporosis Fracture
The Effect of Semaglutide on Bone Health
Semaglutide has effects that include lowering blood sugar, reducing weight, and improving cardiovascular and renal outcomes, and it is now widely used in clinical practice.
- Conditions
- Osteoporosis, Osteoporosis Fracture, T2DM
- Trial name
- NCT07165158
- Testing
- semaglutide combined with metformin
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Type 2 Diabetes Mellitus (T2DM), Obesity and Overweight
CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes
The goal of this clinical trial is to learn if treatment with CK-0045 improves blood sugar control after a meal in participants with type 2 diabetes mellitus (T2DM) and overweight/obesity.
- Trial name
- NCT06611930
- Testing
- CK-0045
- Where
- 2 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Cytoki Pharma
Type 2 Diabetes Mellitus
Secondary Prevention in Type 2 Diabetes: Comparison of Two Different Resistance Exercise Training Protocols
Skeletal muscle accounts for up to 40% of the total body weight and is responsible for approximately 75% of the whole body insulin-stimulated glucose uptake.
- Trial name
- NCT01218256
- Testing
- Physical exercise training
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Paracelsus Medical University